Daratumumab in combination (with bortezomib, lenalidomide, and dexamethasone) [DAR6]

For UNTREATED multiple myeloma when a stem cell transplant is UNSUITABLE where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant, or internally accredited haematology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
2. The patient has newly diagnosed multiple myeloma.

Note

Note: this daratumumab indication is not funded for patients with primary amyloidosis. Please confirm this by ticking the box below: - this patient does not have a diagnosis of primary amyloidosis

3. The patient has previously not received any systemic anti-cancer therapy for myeloma except for either an emergency use of a short course of corticosteroids before this treatment or the patient commenced induction therapy with the combination of daratumumab plus bortezomib, thalidomide and dexamethasone with the intention of proceeding to a stem cell transplant but despite responding to such treatment the patient is now ineligible for transplantation. Please tick below which scenario applies to this patient:

• the patient has not received any prior systemic anti-cancer therapy
• the patient has only had an emergency use of a short course of corticosteroids
• the patient commenced induction therapy with the combination of daratumumab plus bortezomib, thalidomide and dexamethasone with the intention of proceeding to a stem cell transplant but despite responding to such treatment the patient is now ineligible for transplantation.

Note

Note: patients who have not responded to induction therapy with daratumumab plus bortezomib, thalidomide and dexamethasone are NOT allowed to switch to the daratumumab combination regimen outlined in this Blueteq form.

4. The patient is ineligible for an autologous stem cell transplant.
5. Daratumumab will only be given in combination with bortezomib, lenalidomide and dexamethasone and that it is not to be used in combination with any other agents.
6. The patient is of ECOG performance status 0, 1 or 2 Please tick one of the boxes below:

• performance status 0 or
• performance status 1 or
• performance status 2

7. Daratumumab in combination with bortezomib, lenalidomide and dexamethasone will continue to be given until the development of progressive disease, unacceptable toxicity, or patient choice to stop treatment, whichever occurs first.
8. When a treatment break of more than 6 weeks beyond the expected 4-, or 6- (cycle one and two only) weekly cycle length is needed, the prescribing clinician will complete a treatment break approval form to restart treatment, which MUST be approved before treatment is re-commenced.
9. Daratumumab will be otherwise be used as set out in its Summary of Product Characteristics.

CDF funded From: 08 June 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.403 of the CDF list, downloaded from NHS England’s website on 18 June 2026 at 09:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.